Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.

Scientific reports - 27 Feb 2026

Xiao Jiayi, Cai Qinyi, Li Xinyuan, Zhang Degang

Abstract excerpt

MET exon 14 skipping mutations (METex14) or amplification drives a subset of non-small cell lung cancer (NSCLC). Tepotinib, a selective MET tyrosine kinase inhibitor (TKI), has shown promise in early trials; however, comparative efficacy and safety data across MET-altered subpopulations remain limited. This systematic review of six studies (546 patients) assessed the clinical outcomes of Tepotinib in METex14 or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Pyridazines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 41760894
DOI: 10.1038/s41598-026-41989-z
PMCID: PMC13049086

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.PMID 41760894Read ↗

A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).Semantic proximity Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.Semantic proximity Read ↗

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.Semantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.Semantic proximity Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.